Relationship Between Metabolic Dysfunction-Associated Steatotic Liver Disease and Lipoprotein (a) and Other Biomarkers.

Autor:	Muñoz Rossi FA; Internal Medicine, National University of Colombia, Bogota, COL., Salazar Agudelo J; Emergency Medicine, CES Clinic, Medellin, COL., Quinapanta Castro NI; Research and Biostatistics, Regional Autonomous University of the Andes, Ambato, ECU., Mosquera SZ; Emergency Medicine, CES Clinic, Medellin, COL., Mejia Fajardo MC; General Medicine, Cooperative University of Colombia, Medellín, COL., Mosquera López ED; General Medicine, Universidad Central del Ecuador, Quito, ECU., Espitia Olarte JD; Internal Medicine, National University of Colombia, Bogota, COL., Figueroa Medina MA; General Medicine, Libre University of Colombia, Barranquilla, COL., Zuniga Simancas E; Internal Medicine, Sinu University/General Clinic of the Caribbean/Blas de Lezo Clinic/Cardiovascular and Metabolic Center, Cartagena, COL., Saldarriaga Osuna LF; General Physician, National University of Colombia, Bogota, COL.
Jazyk:	angličtina
Zdroj:	Cureus [Cureus] 2024 Jun 24; Vol. 16 (6), pp. e63019. Date of Electronic Publication: 2024 Jun 24 (Print Publication: 2024).
DOI:	10.7759/cureus.63019
Abstrakt:	Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) primarily affects the adult population and is closely related to obesity. The most severe form of MASLD, metabolic dysfunction-associated steatohepatitis (MASH), can progress to liver fibrosis. While lipoprotein(a) (Lp(a)) is known to be associated with cardiovascular disease, its relationship with MASLD remains unclear. This study aims to determine the prevalence of MASLD in ambulatory patients and to explore the association between Lp(a) levels and advanced liver damage. Methods: This retrospective cross-sectional study included 130 patients older than 18 years seen in a healthcare center in Medellin, Colombia, between April 2023 and May 2024. Sociodemographic, clinical, and specific biomarker data were collected. Patients with cirrhosis, previous liver disease, frequent alcohol consumption, cancer, and other severe conditions were excluded. Continuous variables were analyzed using Student's t-tests or Mann-Whitney tests according to their distribution, and categorical variables were analyzed using contingency tables and chi-square tests. Results: Of the 130 patients, 57.9% (n=73) had MASLD, with a higher prevalence in patients with obesity (80%, n=32). Lp(a) levels were abnormally high in 43.1% (n=31) of patients; however, a weak but significant inverse correlation was found between Lp(a) levels and the Fibrosis-4 (FIB-4) score, which is used to assess the severity of liver fibrosis. Patients with MASLD had significantly lower high-density lipoprotein (HDL) and vitamin D levels, and higher levels of gamma-glutamyl transferase (GGT). Conclusions: This study highlights the significant prevalence of MASLD in outpatients and its relationship with various biomarkers, including Lp(a), HDL, vitamin D, and GGT. Although the findings suggest a possible utility of Lp(a) as a biomarker in MASLD, longitudinal studies are needed to confirm these associations and clarify their role in liver disease progression. The study's limitations include its cross-sectional nature and potential selection bias, indicating the need for further research to validate these results. Competing Interests: Human subjects: Consent was obtained or waived by all participants in this study. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work. (Copyright © 2024, Muñoz Rossi et al.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu